Australian Cardiovascular Alliance

Cardiovascular research benefiting all Australians

The Australian Cardiovascular Alliance (ACvA) is the peak leadership body in the country for the advancement of heart, stroke and vascular disease research.

It is a comprehensive collaboration of the very highest quality cardiovascular research bodies and scientific societies, individual researchers, industry and non-government organisations in Australia and is uniquely positioned to leverage key interactions between Australia’s strong research capability and the health system to improve health outcomes and reduce costs.

 

A Snapshot of Australia’s Cardiovascular Health

 

1 in 4 deaths in Australia are from CV disease, killing one Australian every 13 minutes.

 

At $10.4 billion annually, CV disease is Australia’s highest disease expenditure.

 

Atherosclerosis is the major underlying cause of CV disease and contributes significantly to heart attacks and strokes.

 

Heart failure will affect 20% of adults in their lifetime.

 

56,000 strokes in Australia in 2017; 65% of survivors are unable to carry out daily living activities unassisted.

 

One Australian limb lost every
2 hours due to complications of diabetes and peripheral arterial disease.

 

1.1 million hospitalisation for CV in 2016-17 accounting for 11% of all hospitalisation.

 

CVD disease disproportionately affects indigenous, remote and socioeconomically disadvantaged Australians.

As a member-based organisation, the ACvA believes the time is ripe for a new vision, new thinking and new strategies to solve cardiovascular disease.

We have developed a strong case for investment in cardiovascular health that represents a step change for cardiovascular health, bringing together our entire cardiovascular research community and promoting a whole-of-nation approach along a bi-directional translational pipeline. This will ensure that our talented researchers are aligned to the most urgent clinical challenges and that discoveries and innovative approaches to care are translated to the bedside in an accelerated manner. These ambitious objectives can only be met through significant investment, leadership and collaboration.

The ACvA brings expertise that spans fundamental biomedical research through to global clinical trial and public health bodies.

We work in partnership with the Heart Foundation, and industry members committed to the improvement of cardiovascular health in Australia. We are deeply engaged with the NHMRC-recognised Australian Health and Research Translational Centres and extend into primary care, which is essential for health impact.

ACvA Latest News

ACvA Board Communique June 2021

This communique highlights key discussions and considerations from the ACvA Strategy Day 2021.   Context The ACvA Strategy Day was held 6 May 2021 at the Boston Consulting Group Office, Sydney, and virtually. Attendees included members of the ACvA Board, Flagship...

read more

ACvA Latest Video

 

Winners from the Ozheart Song Contest!

ACvA Latest Tweets

Looking forward to this webinar!

Register here: https://zoom.us/meeting/register/tJctce2qrTojH9I5Oz7Wrpq1TsxLZoKOM-sk

UPCOMING ACvA WEBINAR: Commercialisation Stories

Join us Friday 24 Sept 12:30 - 1:30pm AEST to hear from Prof Avril Robertson (Inflazome) and Prof Tony Weiss (Elastagen) on their journey from discovery to commercialisation!

REGISTER HERE: https://zoom.us/meeting/register/tJctce2qrTojH9I5Oz7Wrpq1TsxLZoKOM-sk

Today is the first day of Atrial Fibrillation Awareness Week! Palpitations are among the most common Atrial Fibrillation (AF) symptoms. If you or someone you know has recently experienced palpitations, get a heart check from your GP today.
#AFwarenessWeek #FeeltheBeat

"Crossing the Quality Chasm: Why Improving Heart Failure Care May Save US Health Care" by Dr. Adam DeVore - Outstanding #cvcgrandrounds by @_adevore! @umichCVC @nadia_sutton @tkoellin @JRGolbus #ACCEmergingFaculty @KBerlacher

3